The Best Peptides for Anti-Aging: Epithalon, GHK-Cu, and NAD+ Explained

Aging is not a single process but a collection of overlapping biological changes: shortening telomeres, declining mitochondrial function, accumulating cellular senescence, reduced collagen production, and rising chronic inflammation. Anti-aging peptides are short chains of amino acids that researchers study because they can interact with specific receptors, enzymes, or signaling pathways involved in one or more of these processes. Unlike broad-spectrum supplements, peptides are valued for their specificity — a property that, in theory, allows them to nudge a single biological pathway without disrupting everything around it.

To understand why peptides attract so much attention in longevity circles, it helps to remember that the human body already produces over 7,000 known peptides, many of which act as hormones, growth factors, and signaling molecules. As we age, the natural concentration of several of these declines. The copper tripeptide GHK, for example, is present in human plasma at roughly 200 ng/mL around age 20 and falls steadily through midlife. Synthetic or supplemental peptides aim to restore or amplify signals that the aging body produces less efficiently.

It is important to set expectations honestly. The peptides most often marketed for anti-aging fall into two very different evidence categories. Cosmetic peptides applied topically — such as GHK-Cu, Matrixyl, and Argireline — have human clinical data and are widely used in approved skincare products. Systemic longevity peptides such as Epithalon are supported largely by preclinical and small human studies, often from a narrow group of laboratories, and have not been validated by large, independent clinical trials.

This article focuses on three names that dominate the anti-aging conversation — Epithalon, GHK-Cu, and NAD+ — alongside a few notable alternatives. If you are new to this topic, our overview of what peptides are provides helpful background before diving into specific mechanisms.

This article is for educational purposes only and is not medical advice. The peptides discussed are largely classified for research use and are not approved as anti-aging therapies. Consult a healthcare professional before use.

Epithalon (also spelled epitalon or epithalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). It was developed in Russia as a synthetic analogue of epithalamin, a natural extract of the pineal gland, by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The pineal gland regulates circadian rhythms and melatonin production, both of which become less robust with age, and epithalon was designed to support pineal signaling.

The most discussed property of epithalon is its reported ability to activate telomerase, the enzyme that maintains the protective telomere caps at the ends of chromosomes. Telomeres shorten with each cell division, and critically short telomeres are associated with cellular senescence. In cultured human cells, Khavinson's group reported that epithalon could induce telomerase activity and extend the proliferative capacity of somatic cells. This is the mechanistic basis for claims that epithalon “slows aging” at the cellular level.

Beyond telomeres, animal studies from the same research lineage have reported effects on melatonin rhythm restoration, antioxidant capacity, and, in some long-term rodent experiments, reductions in spontaneous tumor incidence and modest increases in lifespan. A frequently cited multi-year human observational study reported reduced mortality in older patients given peptide preparations, though its design and independence have been questioned by outside reviewers.

The honest scientific picture is one of intriguing but unconfirmed findings. The bulk of positive evidence originates from a small number of affiliated research groups, much of it published decades ago, and has not been replicated in large, randomized, placebo-controlled trials by independent Western laboratories. Telomerase activation also raises a legitimate theoretical concern: because many cancer cells rely on telomerase to divide indefinitely, chronically upregulating it is not without risk. Epithalon is not approved by the FDA or EMA and is sold strictly as a research peptide.

For readers building a broader picture of how peptides are combined in longevity protocols, our guide to peptide stacking discusses the principles and pitfalls of layering multiple compounds.

GHK-Cu is a copper-binding tripeptide composed of glycine, L-histidine, and L-lysine bound to a copper ion. It was discovered in 1973 by biochemist Loren Pickart, who observed that a factor in young human plasma could restore more youthful function to aged liver tissue — a factor later identified as GHK. Because its natural plasma concentration declines markedly with age, GHK-Cu has become one of the most extensively researched and commercially adopted anti-aging peptides, particularly in cosmetic formulations.

GHK-Cu's appeal rests on a remarkably broad mechanism of action. In fibroblast and gene-expression studies, GHK-Cu has been shown to stimulate collagen synthesis by up to 70%, increase production of elastin and glycosaminoglycans, and accelerate wound healing — with some clinical studies reporting roughly 30% faster epithelialization. At the genomic level, research has documented that GHK-Cu can influence the expression of over 60 genes, many tied to tissue remodeling, antioxidant defense, and DNA repair, which helps explain its wide-ranging effects on skin quality.

For topical anti-aging, the human evidence is comparatively strong. Controlled cosmetic studies have reported improvements in skin firmness, density, fine lines, and clarity with GHK-Cu-containing creams and serums. Unlike many longevity peptides, GHK-Cu is found in numerous over-the-counter skincare products, and its topical safety profile is well established when used at appropriate concentrations. Our dedicated GHK-Cu guide covers formulation, concentration, and usage in detail.

Search interest reflects this momentum: GHK-Cu search volume grew by more than 1,000% year-over-year between 2025 and 2026, making it one of the fastest-rising peptides in consumer awareness. That popularity, however, also means quality varies widely between products, and copper peptides can be destabilized by certain other actives such as direct vitamin C, which matters for anyone layering ingredients.

It is worth distinguishing topical from injectable use. The robust data supports topical GHK-Cu for skin. Systemic injection for broader anti-aging effects is far less studied in humans and should be regarded as experimental. Readers comparing GHK-Cu with classic actives may find our analysis of peptides versus retinol useful for deciding where each fits.

Before anything else, an honest clarification: NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It is a coenzyme — a small molecule derived from vitamin B3 — not a chain of amino acids. We include it here because it appears constantly alongside Epithalon and GHK-Cu in anti-aging and longevity protocols, and readers deserve to understand why it belongs to a different biochemical class even when it is marketed in the same breath.

NAD+ is essential to life. It serves as a critical electron carrier in mitochondrial energy production and acts as a substrate for two important enzyme families: the sirtuins (linked to DNA repair, metabolic regulation, and longevity signaling) and PARPs (involved in repairing damaged DNA). When NAD+ is abundant, these systems function efficiently. The challenge is that cellular NAD+ levels decline substantially with age, which researchers believe contributes to reduced mitochondrial efficiency and impaired repair capacity in older tissues.

This decline is the rationale behind NAD+ “boosting” strategies, which typically use precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), or direct NAD+ administration via IV or injection. Animal studies have shown encouraging effects on metabolic health, mitochondrial function, and certain markers of aging when NAD+ levels are restored. Early human trials of NR and NMN have demonstrated that these precursors can reliably raise blood NAD+ levels and are generally well tolerated.

However, raising NAD+ levels is not the same as proving it slows human aging. Human outcome data on lifespan or major age-related disease endpoints remain limited and mixed. NMN's regulatory status has also shifted in the United States, where the FDA has taken the position that NMN cannot be marketed as a dietary supplement, creating a complicated and evolving legal landscape. Anyone considering NAD+ pathways should treat the longevity claims as promising but unproven and discuss them with a physician.

In practice, the NAD+ story complements rather than competes with peptide approaches: peptides like GHK-Cu act on tissue signaling and structure, while NAD+ supports the metabolic and repair machinery inside cells. They address different hallmarks of aging.

Epithalon, GHK-Cu, and NAD+ dominate the headlines, but several other peptides feature prominently in anti-aging discussions, each with a distinct mechanism and a different level of supporting evidence. Understanding the broader landscape helps put the top three in context.

Matrixyl (palmitoyl pentapeptide / Matrixyl 3000) is a cosmetic peptide designed to signal fibroblasts to produce more collagen, mimicking the body's natural repair response to skin damage. Manufacturer-sponsored research reports that Matrixyl 3000 can increase collagen synthesis by up to 117%, and it appears in a large share of premium anti-wrinkle products. Argireline (Acetyl Hexapeptide-3) works very differently, partially inhibiting the neurotransmitter release involved in facial muscle contraction — a topical, milder mechanism sometimes described as “Botox-like,” with studies reporting wrinkle-depth reduction of up to 30% over 30 days.

On the regenerative side, peptides such as BPC-157 and TB-500 (Thymosin Beta-4) are studied primarily for tissue repair rather than aging per se, though improved recovery and reduced inflammation are sometimes framed in anti-aging terms. It bears repeating that these have extensive preclinical data but essentially zero completed Phase III human trials, and they remain research compounds. Growth-hormone-related peptides such as CJC-1295 are likewise discussed for their downstream effects on body composition and skin, but they carry meaningful hormonal considerations and require medical oversight.

A more experimental category includes senolytic peptides such as FOXO4-DRI, designed to selectively trigger death in senescent (“zombie”) cells that accumulate with age and drive inflammation. These represent a genuinely exciting frontier in aging biology, but the human evidence is currently minimal and they should be considered strictly investigational.

For a fuller ranking and discussion of the leading options across categories, see our overview of the best peptides overall and our focused guide to peptides for skin.

The table below summarizes the primary mechanism, main target of action, route, and evidence strength for the leading anti-aging compounds discussed in this article. Evidence strength reflects the quality and independence of available human data, not the enthusiasm of marketing claims.

A few patterns stand out. The compounds with the strongest, most independent human evidence are the topical cosmetic peptides — GHK-Cu, Matrixyl, and Argireline — because they have been formulated into regulated consumer products and tested in controlled skin studies. The systemic longevity candidates, Epithalon foremost among them, sit lower on the evidence ladder despite generating the most dramatic claims.

This is the central tension of the anti-aging peptide field: the compounds that promise the most (slowing biological aging itself) tend to have the least rigorous human validation, while the compounds with solid data make more modest promises (better skin quality and appearance). A clear-eyed strategy weights both the size of the claimed benefit and the quality of the proof behind it. For deeper monographs on individual compounds, our cosmetic peptides guide is a useful next step.

Separating evidence from hype is the single most valuable skill when evaluating anti-aging peptides. The marketing around longevity compounds frequently blurs the line between a plausible mechanism, a result in cell culture, a finding in rodents, and a demonstrated benefit in humans. These are four very different levels of certainty, and only the last reliably predicts what a compound will do in your body.

For GHK-Cu, the topical evidence is genuinely encouraging: multiple studies support its ability to improve measurable aspects of skin structure and appearance, and it is used in regulated products. Even here, though, results depend heavily on formulation quality, concentration, and consistent use — not every product labeled “copper peptide” delivers an effective dose. The proven benefit is improved skin quality, not reversal of systemic aging.

For Epithalon, the situation is more cautionary. The telomerase and longevity findings are scientifically interesting, but they rest disproportionately on work from affiliated laboratories, often with small samples, older methodology, and limited independent replication. Extraordinary claims — such as extending human lifespan — require extraordinary, reproducible evidence that simply does not yet exist for this peptide. Treat it as a research compound under investigation, not a validated therapy.

For NAD+, precursor supplements demonstrably raise NAD+ levels and appear safe in the short term, but the leap from “raises a biomarker” to “slows aging or prevents disease” remains unproven in humans. Several well-designed trials are ongoing, and the next few years should clarify the picture considerably. Until then, optimism should be tempered with patience.

The responsible bottom line: no peptide or supplement has been proven to stop or reverse human aging. The realistic, evidence-supported benefits center on skin appearance and possibly metabolic support. Anyone promising more than that is selling certainty the science has not delivered. This section is educational and does not constitute medical advice.

If you are considering anti-aging peptides, safety and legality should come before efficacy. The most important fact to understand is regulatory: most systemic research peptides — including Epithalon, BPC-157, TB-500, and CJC-1295 — are classified “for research use only” in the United States and European Union. They are not approved by the FDA or EMA as anti-aging treatments, and the FDA has issued warning letters to companies marketing unapproved peptide products. Legal status varies significantly by jurisdiction, and possession or import rules differ from country to country.

Quality and sourcing are a second major concern. Because research peptides exist in a lightly regulated gray market, products can vary widely in purity, dosing accuracy, and sterility. Contamination, mislabeling, and underdosing are real risks. This is one reason topical cosmetic peptides — sold in regulated consumer products — carry a clearer safety profile than injectable research compounds sourced online.

From a biological standpoint, peptides generally produce fewer off-target side effects than small-molecule drugs because of their specificity, but “fewer” does not mean “none.” Injectable peptides carry risks of injection-site reactions and infection, and compounds that alter hormonal or proliferative signaling (such as growth-hormone peptides or telomerase activators) carry theoretical longer-term risks that have not been fully characterized in humans. Athletes should also note that the World Anti-Doping Agency monitors peptide hormones and growth factors under its S2 category.

The most prudent approach is straightforward. Start with the best-evidenced, lowest-risk options — well-formulated topical GHK-Cu and cosmetic peptides — if your goal is skin appearance. Treat systemic longevity peptides as experimental, and never self-administer injectables without medical supervision. Above all, consult a qualified healthcare professional who can review your individual health profile, medications, and goals.

For more on responsible use, our medical disclaimer and safety resource outlines the limitations of this kind of information. This article is for educational purposes only, describes compounds that are largely not approved for human use, and is not a substitute for professional medical advice.